Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 2/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547785 | 1.00 | CYP11B1 (0.56) | CYP11B1CYP11B2CYP2A6CDK9GSK3A | |
| Ammonia Solution, Strong SCHEMBL27725592 | 0.98 | CYP11B1 (0.55) | CYP11B1CYP11B2CYP2A6CDK9GSK3A | |
| Water SCHEMBL28177305 | 0.98 | CYP11B1 (0.55) | CYP11B1CYP11B2CYP2A6CDK9GSK3A | |
| SCHEMBL692484 | 0.91 | CYP11B1 (0.52) | CYP11B1CYP11B2CYP2A6CDK9GSK3A | |
| SCHEMBL30368907 | 0.91 | CYP11B1 (0.52) | CYP11B1CYP11B2CYP2A6CDK9GSK3A | |
| SCHEMBL31595960 | 0.89 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP2A6CDK9GSK3A | |
| Hydrochloric Acid SCHEMBL2241644 | 0.89 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP2A6CDK9GSK3A | |
| Formic Acid SCHEMBL28223024 | 0.89 | CYP11B1 (0.47) | CYP11B1CYP11B2CYP2A6CDK9GSK3A | |
| Biphenyl SCHEMBL27880420 | 0.89 | CYP11B1 (0.60) | CYP11B1CYP11B2CYP2A6CDK9GSK3A | |
| SCHEMBL28933997 | 0.84 | CYP11B1 (0.59) | CYP11B1CYP11B2CDK9CDK5CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1038 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954771-A | Water-soluble AIE functional molecule and application thereof in latent fingerprint imaging | 辽宁石油化工大学 | 2025-05-09 | — | — | CN | claimed |
| CN-119331601-A | Preparation and application methods of room-temperature phosphorescent material based on octatomic cucurbituril and 6-bromoisoquinoline derivatives | 贵州大学 | 2025-01-21 | — | — | CN | claimed |
| CN-118546089-A | Tetrahydroisoquinoline derivative and application thereof as acrB efflux pump inhibitor with membrane permeabilization function in antibiosis | 山东大学 | 2024-08-27 | — | — | CN | claimed |
| CN-114805204-B | Method for preparing 4-iodoisoquinoline-1 (2H) -ketone compound | 云南师范大学 | 2023-09-15 | — | — | CN | claimed |
| CN-111606895-B | Synthesis method of 1-alkyl-isoquinoline compound | 武汉英纳氏药业有限公司 | 2021-12-21 | — | — | CN | claimed |
| CN-108084090-B | Synthetic method of brominated compound containing nitrogen heterocycle as drug intermediate | 北京六合宁远科技有限公司 | 2020-03-17 | — | — | CN | claimed |
| CN-106831575-B | A kind of preparation method of 1- aminoisoquinoline -6- methanol | 北京六合宁远科技有限公司 | 2019-04-16 | — | — | CN | claimed |
| CN-106831576-B | Preparation method of 2-methyl-1-oxo-1, 2-dihydroisoquinoline-6-formic acid | 北京六合宁远科技有限公司 | 2019-04-16 | — | — | CN | claimed |
| US-10125226-B2 | Scale-up process of bifunctionalized triblock copolymers with secondary and tertiary amines, with application in dewatering and desalting of heavy crude oils | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2018-11-13 | — | — | US | claimed |
| CN-108084090-A | Synthetic method of brominated compound containing nitrogen heterocycle as drug intermediate | 北京六合宁远科技有限公司 | 2018-05-29 | — | — | CN | claimed |
| CN-106831576-A | Preparation method of 2-methyl-1-oxo-1, 2-dihydroisoquinoline-6-formic acid | 北京六合宁远科技有限公司 | 2017-06-13 | — | — | CN | claimed |
| CN-106831575-A | A kind of preparation method of the methyl alcohol of 1 aminoisoquinoline 6 | 北京六合宁远科技有限公司 | 2017-06-13 | — | — | CN | claimed |
| CN-104370813-A | Preparation method of isoquinoline-6-formaldehyde | UNIV SHANGHAI | 2015-02-25 | — | — | CN | claimed |
| US-20140364566-A1 | SCALE-UP PROCESS OF BIFUNCTIONALIZED TRIBLOCK COPOLYMERS WITH SECONDARY AND TERTIARY AMINES, WITH APPLICATION IN DEWATERING AND DESALTING OF HEAVY CRUDE OILS | INSTITUTO MEXICANO DEL PETROLEO (MX) | 2014-12-11 | — | — | US | claimed |
| US-20260137677-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | TOCRIS COOKSON LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4741397-A1 | FUSED TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen Zhongge Biological Technology Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260116896-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2026-04-30 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999020608-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116896-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, GLRB, NR1D2 | CYP11B1 1906/4885CYP11B2 2174/4885CYP2A6 2449/4885 |
| US-20260137677-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | XIAP, MDM2, SARS1 | CYP11B1 4443/4885CYP11B2 4376/4885CYP2A6 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.